***Background.*** Informative data on microbiologically-evaluable (ME) complicated urinary tract infection (cUTI) typically arise from clinical trials. Characterization of ME cUTI in electronic medical record (EMR)-linked administrative databases will provide standards of care diagnostics, treatments, and outcomes in broader populations.

***Methods.*** Retrospective cohort study was conducted to characterize ME cUTI cases in Health Facts®, Cerner Corp, Kansas City, MO. Inclusion criteria were \>18 years old with cUTI hospital episode in years 2008-2010 defined by International Classification of Diseases, 9th Revision, Clinical Modification codes, a urine culture report, and \>1 antimicrobial prescription. Descriptive analyses were conducted in SAS version 9.1.3 (The SAS Institute, Cary, NC).

***Results.*** Final cohort of 7754 adults was selected from 1.2 million hospital episodes. There were 4634 (60%) women, 53% were \>65 years old, 3789 (49%) had acute pyelonephritis (AP), and 5566 (72%) had ME urine cultures. Comorbidities, categorized by Clinical Classifications Software, revealed age-stratified distinctions. Among ME cUTI subjects, a single, definitive pathogen was reported for 78% with AP and 63% in non-AP. In AP, the top-ranked pathogens were *Escherichia coli* (55%), *Klebsiella pneumoniae* (7%), and *Proteus mirabilis* (5%); in non-AP these were *E. coli* (26%), *Pseudomonas aeruginosa* (8%), and *Enterococcus faecalis*(8%). Among isolates with susceptibility data, multidrug-resistance (MDR) to \>3 drug classes was detected in 7% Enterobacteriaceae and 14% non-Enterobacteriaceae. Initial treatment, by drug class, was highest for fluoroquinolones (26%), extended-spectrum cephalosporins (21%), and glycopeptides/oxazolidinones (13%). In ME cUTI subjects, 1193 (21%) had bacteremia with the same uropathogen. Overall mean length of stay was 7.7 (SD 9.3) days and 147 (2%) had in-hospital mortality.

***Conclusion.*** This study provides recent epidemiology of ME cUTI and MDR pathogens in hospitalized adults. The algorithms created to identify the urine specimen, pathogens, and susceptibility data in the microbiology files provide a framework for detection of MDR pathogens in future population-based studies using EMR-linked observational data sources.
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